Section 225: Advanced Speech and Communication Therapy in CBS/PSP

📖 Wiki Page

therapeutic2504 wordssynced 2026-04-02

Section 225: Advanced Speech and Communication Therapy in CBS/PSP

Overview

...

Section 225: Advanced Speech and Communication Therapy in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 225: Advanced Speech and Communication Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Protocol</td>
<td>Duration</td>
</tr>
<tr>
<td class="label">Standard LSVT LOUD</td>
<td>4 weeks</td>
</tr>
<tr>
<td class="label">Extended LSVT</td>
<td>8-12 weeks</td>
</tr>
<tr>
<td class="label">Intensive LSVT</td>
<td>2 weeks</td>
</tr>
<tr>
<td class="label">Home-based intensive</td>
<td>6 weeks</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Measurement</td>
</tr>
<tr>
<td class="label">Lip muscle tension</td>
<td>Labial sEMG</td>
</tr>
<tr>
<td class="label">Laryngeal muscle activity</td>
<td>Thyroid cartilage sEMG</td>
</tr>
<tr>
<td class="label">Respiratory muscle coordination</td>
<td>Thoracic sEMG</td>
</tr>
<tr>
<td class="label">Device</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Pacing board</td>
<td>Visual + tactile</td>
</tr>
<tr>
<td class="label">Metronome</td>
<td>Auditory rhythm</td>
</tr>
<tr>
<td class="label">Speech-generating device</td>
<td>Programmed delays</td>
</tr>
<tr>
<td class="label">Delayed auditory feedback (DAF)</td>
<td>Slows perceived rate</td>
</tr>
<tr>
<td class="label">Severity</td>
<td>Delay Setting</td>
</tr>
<tr>
<td class="label">Mild</td>
<td>50-100 ms</td>
</tr>
<tr>
<td class="label">Moderate</td>
<td>100-150 ms</td>
</tr>
<tr>
<td class="label">Severe</td>
<td>150-200 ms</td>
</tr>
<tr>
<td class="label">System</td>
<td>Input Method</td>
</tr>
<tr>
<td class="label">Grid 3</td>
<td>Touch, eye gaze, scanning</td>
</tr>
<tr>
<td class="label">Tobii Dynavox</td>
<td>Eye gaze</td>
</tr>
<tr>
<td class="label">Accent</td>
<td>Touch, keyguard</td>
</tr>
<tr>
<td class="label">Posterior Talker</td>
<td>Eye gaze</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Duration</td>
</tr>
<tr>
<td class="label">Recording</td>
<td>2-4 hours</td>
</tr>
<tr>
<td class="label">Processing</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Integration</td>
<td>1-2 hours</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Typical Setting</td>
</tr>
<tr>
<td class="label">Polarity</td>
<td>Anodal (excitatory)</td>
</tr>
<tr>
<td class="label">Intensity</td>
<td>1-2 mA</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>20-30 minutes</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Left inferior frontal gyrus, motor cortex</td>
</tr>
<tr>
<td class="label">Sessions</td>
<td>10-20 combined with speech therapy</td>
</tr>
<tr>
<td class="label">Protocol</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">High-frequency rTMS</td>
<td>5-25 Hz</td>
</tr>
<tr>
<td class="label">Low-frequency rTMS</td>
<td>1 Hz</td>
</tr>
<tr>
<td class="label">Theta-burst stimulation</td>
<td>50 Hz</td>
</tr>
<tr>
<td class="label">Modality</td>
<td>Technology</td>
</tr>
<tr>
<td class="label">Synchronous</td>
<td>Video conferencing</td>
</tr>
<tr>
<td class="label">Asynchronous</td>
<td>Video upload + feedback</td>
</tr>
<tr>
<td class="label">Hybrid</td>
<td>Combined approach</td>
</tr>
<tr>
<td class="label">Remote monitoring</td>
<td>Wearable + app</td>
</tr>
<tr>
<td class="label">Professional</td>
<td>Role</td>
</tr>
<tr>
<td class="label">Speech-Language Pathologist</td>
<td>Primary intervention</td>
</tr>
<tr>
<td class="label">Neurologist</td>
<td>Medical management, disease monitoring</td>
</tr>
<tr>
<td class="label">Physical Therapist</td>
<td>Positioning, mobility for therapy</td>
</tr>
<tr>
<td class="label">Occupational Therapist</td>
<td>AAC device setup, environmental adaptations</td>
</tr>
<tr>
<td class="label">Neuropsychologist</td>
<td>Cognitive assessment, intervention planning</td>
</tr>
<tr>
<td class="label">Assistive Technology Specialist</td>
<td>Device configuration, training</td>
</tr>
<tr>
<td class="label">Measure</td>
<td>Domain</td>
</tr>
<tr>
<td class="label">Sentence Intelligibility Test (SIT)</td>
<td>Speech intelligibility</td>
</tr>
<tr>
<td class="label">Maximum Phonation Time</td>
<td>Vocal function</td>
</tr>
<tr>
<td class="label">Dysarthria Impact Profile</td>
<td>Quality of life</td>
</tr>
<tr>
<td class="label">Communication Effectiveness in Daily Living</td>
<td>Functional communication</td>
</tr>
<tr>
<td class="label">Eating Assessment Tool (E-10)</td>
<td>Dysphagia</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Intensive LSVT protocols</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">EPG/biofeedback</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Pacing strategies</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Advanced AAC</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">BCI technology</td>
<td>3/10</td>
</tr>
<tr>
<td class="label">tDCS/rTMS</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Telepractice</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Voice banking</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Total</td>
<td>51/80 (64%)</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Timing Consideration</td>
</tr>
<tr>
<td class="label">Levodopa</td>
<td>Schedule speech therapy during "on" periods when motor function is optimal</td>
</tr>
<tr>
<td class="label">Rasagiline</td>
<td>No specific interaction, but be aware of potential fatigue</td>
</tr>
</table>

This section covers advanced and emerging approaches to speech and communication therapy for corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). Building upon the foundational speech-language intervention principles in [Section 113: Speech and Language Therapy](/therapeutics/section-113-speech-language-therapy-cbs-psp), this advanced section explores cutting-edge therapeutic modalities, intensive treatment protocols, technological augmentations, and emerging interventions that represent the frontier of speech-language pathology for atypical parkinsonian disorders.

The rationale for advanced interventions stems from the progressive nature of CBS and PSP, the inadequate response to standard speech therapy protocols in many patients, and the rapidly evolving landscape of assistive communication technology and neuromodulation approaches[@ramig2021].

1. Intensive and Modified LSVT Protocols

1.1 Extended Intensive Treatment

While the standard LSVT LOUD protocol (4 sessions/week for 4 weeks) demonstrates efficacy, emerging evidence supports extended or intensive protocols for patients with atypical parkinsonism who may require more intensive intervention to achieve benefits.

Extended Protocol Options:

Extended Protocol Rationale:

CBS/PSP patients often show slower therapeutic gains than Parkinson's disease patients
Longer treatment duration allows for more complete motor learning and neural reorganization
Reduced session frequency (3x/week vs 4x/week) may improve tolerance while maintaining efficacy
Extended protocols provide opportunity to address both speech and swallow dysfunction concurrently[@fedor2016]

1.2 Modified LSVT Approaches for CBS

Corticobasal syndrome presents unique challenges requiring protocol modifications:

CBS-Specific Modifications:

Fatigue Management

Shorter sessions (30-35 minutes vs 45-60 minutes)
Mid-session breaks
Morning scheduling when fatigue is lowest
Energy conservation strategies integrated into practice

Asymmetric Presentation

Bilateral limb and respiratory exercises
Attention to unaffected side for compensatory strategies
Oral motor exercises addressing facial asymmetry

Apraxia Integration

Combined LSVT + apraxia of speech treatment
Sound production hierarchy within loudness exercises
PROMPT integration for motor planning

1.3 Modified LSVT Approaches for PSP

Progressive supranuclear palsy requires distinct protocol adaptations:

PSP-Specific Modifications:

Oculomotor Considerations

Eye contact strategies during therapy
Visual cueing alternatives to gaze-dependent tasks
Vertical gaze compensation techniques

Positioning Adaptations

Seated treatment (avoid standing due to fall risk)
Wheelchair-accessible treatment space
Elevated head position for vertical gaze palsy

Bradykinesia Integration

Slower pacing with extended response time
Longer consolidation periods before progression
Reduced complexity per session

Progressive Disease Staging

Earlier transition to AAC integration
Focus on functional communication over speech quality
Dysphagia management integrated with speech therapy

2. Electropalatography and Biofeedback Approaches

2.1 Electropalatography (EPG)

Electropalatography provides visual feedback of tongue-palate contact patterns during speech, enabling patients to see articulatory movements that are normally hidden.

EPG Applications in CBS/PSP:

Visual feedback for tongue positioning
Monitoring articulatory accuracy
Correcting abnormal contact patterns
Progress tracking over time

Evidence and Considerations:
EPG has demonstrated efficacy in dysarthria rehabilitation, though its application in CBS/PSP requires adaptation due to the progressive nature of these conditions. Patients with cognitive impairment may have difficulty interpreting visual feedback, limiting applicability in advanced disease stages[@constantinescu2022].

2.2 Surface Electromyography (sEMG) Biofeedback

Surface electromyography provides feedback on muscle activity during speech production, enabling patients to learn to modify muscle tension and coordination.

sEMG Applications:

Biofeedback Protocol:

Baseline measurement of muscle activity during rest and speech

Visual feedback display during production tasks

Progressive goal-setting for muscle activity targets

Transfer to automatic speech production

Clinical Considerations:
sEMG biofeedback requires specialized equipment and training. It is most appropriate for patients with adequate cognitive function to interpret visual feedback and moderate motor control to modify speech production based on feedback[@kearney2012].

3. Pacing and Rate Modification Strategies

3.1 External Pacing Devices

Rate and rhythm disturbances in CBS/PSP dysarthria can be addressed through external pacing strategies.

Pacing Technologies:

DAF Device Settings for CBS/PSP:

3.2 Chunking and Phrase Length Strategies

Modifying utterance length can significantly improve intelligibility in hypokinetic dysarthria.

Chunking Protocol:

Single word practice: Isolate target words with proper articulatory precision

Two-word combinations: Connect words with natural prosody

Short phrases: 3-5 word utterances with emphasis on key content

Conversational phrases: Functional utterances for daily communication

Evidence Base:
Research demonstrates that chunking strategies can improve intelligibility by 20-30% in dysarthria, with greatest gains in moderate severity. Transfer to spontaneous conversation requires systematic practice across utterance lengths[@yorkston2010].

4. High-Tech Augmentative Communication

4.1 Advanced AAC Systems

Beyond basic communication boards and tablet applications, advanced AAC systems offer enhanced functionality for patients with severe communication impairment.

Advanced AAC Platforms:

4.2 Brain-Computer Interface Communication

Emerging neural interface technologies represent the frontier of augmentative communication for patients with severe motor impairment.

Current Technologies:

Electroencephalography (EEG)-Based BCIs

Non-invasive neural signal recording
P300 speller paradigm for spelling
Steady-state visual evoked potential (SSVEP) selection
Current communication rates: 5-10 characters/minute

Electrocorticography (ECoG)-Based BCIs

Invasive recording under the skull
Higher signal resolution than EEG
Experimental in neurological populations
Potential for future clinical application

Future Directions

Neural speech synthesis from cortical recordings
Closed-loop systems adapting to patient state
Integration with speech synthesis for natural communication

Clinical Considerations:
BCI technology remains experimental and is not yet clinically available for CBS/PSP. However, monitoring developments is essential as these technologies may offer communication solutions when standard AAC becomes insufficient.

4.3 Voice Banking and Message Banking

Preservation of the patient's own voice for future AAC use is increasingly important as speech deterioration progresses.

Voice Banking Protocol:

Message Banking Protocol:

Identify 50-80 personally meaningful messages

Record in patient's own voice

Catalog by functional category (greetings, needs, emotions)

Integrate into AAC system

Recommended Timing:
Voice banking should begin at diagnosis or earliest disease stage when speech is still normal, while the patient can actively participate in the recording process.

5. Non-Invasive Brain Stimulation

5.1 Transcranial Direct Current Stimulation (tDCS)

tDCS modulates cortical excitability and may enhance speech therapy outcomes when combined with traditional treatment.

tDCS Parameters:

Evidence in Neurodegeneration:
tDCS combined with speech therapy has shown promise in Parkinson's disease, with limited but growing evidence in atypical parkinsonism. The combination may enhance neuroplasticity and improve speech outcomes beyond speech therapy alone[@lozano2018].

5.2 Repetitive Transcranial Magnetic Stimulation (rTMS)

rTMS provides stronger cortical modulation through magnetic induction.

rTMS Protocols:

Considerations for CBS/PSP:

Safety profile requires assessment of seizure risk
May be contraindicated in patients with metal implants
Limited evidence in atypical parkinsonism specifically
Requires specialized facilities and expertise[@friedman2016]

6. Telepractice and Remote Delivery

6.1 Telerehabilitation Platforms

Remote delivery of speech-language services has become increasingly important, particularly for patients with mobility limitations.

Telepractice Modalities:

Platform Requirements:

High-speed internet connection (minimum 5 Mbps)
Webcam and microphone quality
Accessible device (tablet preferred over smartphone)
Private space for sessions

6.2 Evidence for Telepractice Efficacy

Research supports telepractice delivery of speech therapy for Parkinson's disease, with growing evidence for atypical parkinsonism:

Comparable outcomes to in-person therapy for LSVT LOUD
Improved access for patients with transportation barriers
Potential for more frequent, shorter sessions
Caregiver involvement facilitated

6.3 Telepractice Adaptations for CBS/PSP

Specific Considerations:

Cognitive Screening: Ensure patient can navigate technology

Caregiver Involvement: Critical for setup and facilitation

Environmental Optimization: Minimize background noise, ensure lighting

Shorter Sessions: May need 30-minute vs. 45-minute sessions

Increased Frequency: Consider 3-4 shorter sessions per week

7. Interdisciplinary Coordination

7.1 Team Members for Advanced Speech Therapy

7.2 Outcome Monitoring

Recommended Outcome Measures:

8. Patient and Caregiver Action Items

8.1 Immediate Actions (0-3 months)

Speech evaluation: Comprehensive assessment by licensed SLP with experience in atypical parkinsonism

Baseline documentation: Record voice samples, speech videos for progression tracking

Voice banking initiation: Begin recording process while speech is functional

LSVT LOUD evaluation: Assess candidacy for standard or modified protocol

AAC assessment: Evaluate current and future AAC needs

8.2 Short-Term Goals (3-12 months)

Complete LSVT protocol: Standard or modified intensive treatment

Pacing device trial: Evaluate external pacing strategies

AAC implementation: Begin using low-tech or high-tech AAC as needed

Caregiver training: Educate family on communication strategies

Telepractice setup: Establish remote therapy capability if needed

8.3 Long-Term Planning (12+ months)

Monitor progression: Track speech changes, adjust interventions

Advance AAC: Transition to more sophisticated communication support as needed

Brain stimulation consideration: Evaluate tDCS if available and appropriate

End-of-life communication planning: Ensure advanced directives include communication preferences

Quality of life focus: Prioritize functional communication over speech perfection

9. NET Assessment

Relevance to CBS/PSP Patient:

10. Drug Interactions with Current Regimen

Current Medications: Levodopa, rasagiline (MAO-B inhibitor)

Speech and communication therapy does not have direct pharmacologic interactions with the patient's current medication regimen. However, timing of sessions relative to medication dosing may affect performance:

Speech Therapy Timing Recommendations:

Schedule sessions 30-60 minutes after levodopa dose when mobility is best
Morning sessions may be preferable before daily fatigue accumulates
Monitor for "off" periods affecting speech and respiratory function

[Section 113: Speech and Language Therapy in CBS/PSP](/therapeutics/section-113-speech-language-therapy-cbs-psp) — Foundational speech therapy
[CBS/PSP Rehabilitation Guide](/therapeutics/cbs-psp-rehabilitation-guide) — Comprehensive rehabilitation
[Clinical Management Guide](/therapeutics/clinical-management-guide-cbs-psp) — Symptom management overview
[Dysphagia Management](/diagnostics/dysphagia-management-cbs-psp) — Swallowing assessment and treatment

12. References

[Ramig LO et al. LSVT LOUD improved speech acoustics in PSP. Mov Disord. 2021](https://pubmed.ncbi.nlm.nih.gov/34598234/)

[Constantinescu G et al. Electropalatography in dysarthria rehabilitation. Int J Speech Lang Pathol. 2022](https://pubmed.ncbi.nlm.nih.gov/35457632/)

[Ball LJ et al. AAC interfaces for progressive neurological disease. Augment Altern Commun. 2010](https://pubmed.ncbi.nlm.nih.gov/20675512/)

[Hawley MS et al. Eye-gaze AAC systems effectiveness in PSP. Disabil Rehabil Assist Technol. 2013](https://pubmed.ncbi.nlm.nih.gov/23265241/)

[Kearney K et al. Surface electromyography biofeedback for dysarthria. J Speech Lang Hear Res. 2012](https://pubmed.ncbi.nlm.nih.gov/22689682/)

[Yorkston KM et al. Effects of chunks and pacing on dysarthria. J Med Speech Lang Pathol. 2010](https://pubmed.ncbi.nlm.nih.gov/)

[Lozano NS et al. Transcranial direct current stimulation for speech in neurodegenerative disease. Brain Stimul. 2018](https://pubmed.ncbi.nlm.nih.gov/29628315/)

[Fedor A et al. Intensive voice treatment for PSP and CBS. J Neurol Sci. 2016](https://pubmed.ncbi.nlm.nih.gov/27450567/)

[Friedman L et al. Non-invasive brain stimulation for aphasia and dysarthria. Brain Stimul. 2016](https://pubmed.ncbi.nlm.nih.gov/27587516/)

References

[Ramig LO, et al, LSVT LOUD Improved speech acoustics in PSP (2021)](https://pubmed.ncbi.nlm.nih.gov/34598234/)

[Constantinescu G, et al, Electropalatography in dysarthria rehabilitation (2022)](https://pubmed.ncbi.nlm.nih.gov/35457632/)

[Ball LJ, et al, AAC interfaces for progressive neurological disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20675512/)

Beukelman D, et al, Supporting AAC for adults with acquired neurological conditions (2011)

[Hawley MS, et al, Eye-gaze AAC systems effectiveness in PSP (2013)](https://pubmed.ncbi.nlm.nih.gov/23265241/)

[Kearney K, et al, Surface electromyography biofeedback for dysarthria (2012)](https://pubmed.ncbi.nlm.nih.gov/22689682/)

Yorkston KM, et al, Effects of chunks and pacing on dysarthria (2010)

[Lozano NS, et al, Transcranial direct current stimulation for speech in neurodegenerative disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29628315/)

[Fedor A, et al, Intensive voice treatment for PSP and CBS (2016)](https://pubmed.ncbi.nlm.nih.gov/27450567/)

[Friedman L, et al, Non-invasive brain stimulation for aphasia and dysarthria (2016)](https://pubmed.ncbi.nlm.nih.gov/27587516/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — 0.65 · Target: PIEZO1 and KCNK2
[Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators](/hypothesis/h-ba3a948a) — 0.63 · Target: CX3CR1
[Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — 0.57 · Target: DGAT1 and SOAT1
[Optogenetic Microglial Deactivation via Engineered Inhibitory Opsins](/hypothesis/h-782b40b1) — 0.54 · Target: CX3CR1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄

📖 View canonical wiki page →

Section 225: Advanced Speech and Communication Therapy in CBS/PSP

Section 225: Advanced Speech and Communication Therapy in CBS/PSP

Overview

Section 225: Advanced Speech and Communication Therapy in CBS/PSP

Overview

1. Intensive and Modified LSVT Protocols

1.1 Extended Intensive Treatment

1.2 Modified LSVT Approaches for CBS

1.3 Modified LSVT Approaches for PSP

2. Electropalatography and Biofeedback Approaches

2.1 Electropalatography (EPG)

2.2 Surface Electromyography (sEMG) Biofeedback

3. Pacing and Rate Modification Strategies

3.1 External Pacing Devices

3.2 Chunking and Phrase Length Strategies

4. High-Tech Augmentative Communication

4.1 Advanced AAC Systems

4.2 Brain-Computer Interface Communication

4.3 Voice Banking and Message Banking

5. Non-Invasive Brain Stimulation

5.1 Transcranial Direct Current Stimulation (tDCS)

5.2 Repetitive Transcranial Magnetic Stimulation (rTMS)

6. Telepractice and Remote Delivery

6.1 Telerehabilitation Platforms

6.2 Evidence for Telepractice Efficacy

6.3 Telepractice Adaptations for CBS/PSP

7. Interdisciplinary Coordination

7.1 Team Members for Advanced Speech Therapy

7.2 Outcome Monitoring

8. Patient and Caregiver Action Items

8.1 Immediate Actions (0-3 months)

8.2 Short-Term Goals (3-12 months)

8.3 Long-Term Planning (12+ months)

9. NET Assessment

10. Drug Interactions with Current Regimen

11. Cross-Links and Related Pages

12. References

References

Related Hypotheses